Dactolisib
Dactolisib has been studied in 7 papers since 2018: 1 trial in people, 4 in animals, 2 in cells; 1 in the past year. Its furthest trials in people are at phase 3. The newest paper, Oct 13, 2026: “Targeting PI3K/AKT/mTOR Pathway Exerts Inhibitory Effects on Endothelial Cells from Generalized Lymphatic Anomaly”.
1 new paper in 30 daysSee all 7 papers on dactolisib
At a glance
The findings reach people, from one lab or study. 4 independent labs in 4 countries; 7 trials, 1 about aging, 1 with no results posted.
“we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”
None of its findings points the other way.
- 4 independent labs in 4 countries
- 7 trials, 1 about aging, 1 with no results posted
- Funders: National Institute on Aging and others
- 4 of 9 findings with company ties
- 6 of 7 trials sponsored by its developers
- Human trial1
- Animals2
- Model organisms2
- Cells2
Studies in people
1 study gave dactolisib to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases laboratory-confirmed respiratory tract infectionsOR 0·601 [90% CI 0·391–0·922] no change: Has no effect on clinically symptomatic respiratory illnessOR 1·07 [95% CI 0·80–1·42] | Randomized trial16 weeks | 1,500 peopleaged at least 65 yearsAdults aged at least 65 years | The lancet. Healthy longevity, May 6, 2021 |
What did studies of dactolisib find?
7Studies of dactolisib measured 7 outcomes, among them clinically symptomatic respiratory illness, laboratory-confirmed respiratory tract infections and Endothelial cell functional properties.
Clinically symptomatic respiratory illness
no changein humans1OR 1
1 study
Clinically symptomatic respiratory illness
no changein humans1OR 1
Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (OR 1·07 [95% CI 0·80–1·42]).
“In the full analysis set, RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness, the primary endpoint of the trial”
Human trial16 weeksn = 1,024
The lancet. Healthy longevity
Dactolisib showed no clear effect on clinically symptomatic respiratory illness in humans (phase 3 trial) (26% vs 25%; OR 1·07 (90% CI 0·80-1·42); p=0·65).
“RTB101 did not reduce the proportion of patients with clinically symptomatic respiratory illness”
Human trialphase 3 trial10 mg once daily16 weeksn = 1,024
The lancet. Healthy longevity
Laboratory-confirmed respiratory tract infections
downin humans1
1 study
Laboratory-confirmed respiratory tract infections
downin humans1
Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (OR 0·601 [90% CI 0·391–0·922]).
“In this analysis we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”
Human trial10 mg once daily16 weeks
The lancet. Healthy longevity
Dactolisib decreases laboratory-confirmed respiratory tract infections in humans (phase 2b trial, pooled analysis of parts 1 and 2) (19% vs 28%; OR 0·601 (90% CI 0·391-0·922); p=0·02).
“we found a statistically significant reduction in the proportion of patients who had one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily treatment group”
Human trialphase 2b trial, pooled analysis of parts 1 and 210 mg once daily16 weeks
The lancet. Healthy longevity
Endothelial cell functional properties
downin human cells1
1 study
Endothelial cell functional properties
downin human cells1
Dactolisib decreases endothelial cell functional properties in human cells (GLA-derived endothelial cells from a PIK3CA-mutated sample).
“Finally, pharmacological treatment reduced GLA-EC functional properties and down-modulated the hyperactivated PI3K downstream substrates.”
CellsGLA-derived endothelial cells from a PIK3CA-mutated sample
Cells
Primordial follicle activation
downin mice1
1 study
Primordial follicle activation
downin mice1
Dactolisib decreases primordial follicle activation in mice (slow-frozen ovaries, three weeks after transplantation).
“showed reduced follicle proliferation and activation compared to both control and rapamycin”
Animalsslow-frozen ovaries, three weeks after transplantationovarythree weeks post-grafting
BEZ235-Mediated PI3K/mTOR dual inhibition improves ovarian follicle survival in a preclinical model
Reproductive biology and endocrinology : RB&E
Akt and mTOR pathway activation
downin mice1
1 study
Akt and mTOR pathway activation
downin mice1
Dactolisib decreases akt and mTOR pathway activation in mice (chemotherapy-induced (4-HC) activation in organotypic ovarian culture).
“BEZ235 significantly counteracted chemotherapy-induced activation of both Akt and mTOR pathways”
Animalschemotherapy-induced (4-HC) activation in organotypic ovarian cultureovary1 μM
BEZ235-Mediated PI3K/mTOR dual inhibition improves ovarian follicle survival in a preclinical model
Reproductive biology and endocrinology : RB&E
Lifespan
upin flies1
1 study
Lifespan
upin flies1
Dactolisib extends lifespan in flies.
“We show that the novel anti-ageing drugs, torin2 and dactolisib (BEZ-235), increase longevity in vivo.”
Model organisms
An expedited screening platform for the discovery of anti-ageing compounds in vitro and in vivo
Genome medicine
Cellular senescence
downin human cells1
1 study
Cellular senescence
downin human cells1
Dactolisib decreases cellular senescence in human cells (primary human cells in culture).
“The tested drug treatments reduced senescence and other ageing markers”
Cellsprimary human cells in culture
A CellAgeClock for expedited discovery of anti-ageing compounds
bioRxiv (Cold Spring Harbor Laboratory)Preprint
Has dactolisib been tested in people?
1 of 7 about agingYes: 1 trial in people have been published, and 5 trials are registered.
About aging
Every condition in trials
Phase 3Results posted1 trial
Phase 2Active, not recruiting2 trials
Hereditary Sensory and Autonomic Neuropathies
Phase 2Active, not recruiting2 trials
Virus disease
Phase 2Active, not recruiting2 trials
Phase 1/2Status unknown1 trial
Gliosarcoma
Phase 1/2Status unknown1 trial
Stopped
NCT04409327TerminatedCOVID-19
Insufficient accrual rate
Who is developing dactolisib?
1 company: Restorbio.
- Companies
- RestorbioPhase 2Covid19
Trial sponsors
Company3 trialsPhase 31,120 people
UKRI | Medical Research Council
1 trialPhase 1/258 people